July SASB numbers spike as Australia shoots for a more open minded future

July SASB numbers spike as Australia shoots for a more open minded future

The Therapeutic Goods Administration (TGA) reported 5564 approvals this July for medicinal cannabis in Australia, a 20% increase from the month before. 

FreshLeaf Analytics notes that this brings Australia’s SASB approval total to over 56,000 to date since legislation in 2016.

Tim Drury, Director of Southern Cannabis Holdings, FreshLeaf Analytics’ parent company, commented on July’s numbers: “It is encouraging to see SASB numbers increasing and while some of these patients will be existing patients receiving a new approval, there are also an increasing number of patients entering the market through non-SASB channels such as Authorized Prescriber, research or compounding pathway”.

FreshLeaf also notes that pathways for unapproved medicine such as SASB could become less relevant as more medications are registered. Epidolex from GW Pharmaceuticals which has already been registered in the US is expected to enter the market here in Australia this year, while CBD is likely to become an Over-The-Counter (OTC) medicine next year.

Mr Drury commented, “The possible down-scheduling of CBD to an over-the-counter medicine next year will make access substantially easier and drive significant market growth” 

Changing doctor attitudes and an increasing openness to consider medicinal cannabis as a treatment option are also driving uptake.

General Practitioner Dr Brad Mckay recently commented on Channel 9’s Today Extra that attitudes towards medical cannabis treatments could still improve. 

‘There’s certainly a lot of stigma involved with medicinal cannabis.’

He indicated that from a quantitative perspective, an average drop of 30 percent in use of other medications had been seen across the board after people started on medical cannabis treatments. 

‘They notice that the pain is there, but they’re not as bothered by it.’

The TGA has approved the use of medicinal cannabis on conditions such as chemotherapy-induced nausea and vomiting, refractory paediatric epilepsy, cancer pain, neuropathic pain, spasticity from neurological conditions, anorexia and wasting associated with chronic illness (such as cancer). 

DISCLAIMER: The content on this page and the rest of the website are not meant to relay medicinal cannabis as a definite treatment, but to educate and inform on these treatments. For more information on the Australian medical cannabis industry, please speak to your doctor or call us at 1300 991 477.

Recent blogs

Q3 2020
News

FreshLeaf Q3 Market Report Press Release

Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product

Read More »

Leave a Reply